COVID-19 vaccines: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 vaccines to enable the distribution of promising vaccines in the European Union (EU) as soon as possible. 

COVID-19 vaccines under marketing authorisation evaluation

EMA’s CHMP is evaluating marketing authorisation applications (which may be for conditional marketing authorisation) for the following COVID-19 vaccines:

TreatmentApplicantStart of marketing
authorisation evaluation
More information
SkycovionSK Chemicals GmbH18/08/2022Latest news
Bimervax (previously COVID-19 Vaccine HIPRA)HIPRA Human Health S.L.U.21/03/2023 

COVID-19 vaccines under rolling review

EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the following COVID-19 vaccines under rolling review:

VaccineVaccine developerStart of rolling reviewMore information
Sputnik V,
Russia’s Gamaleya National Centre of Epidemiology and Microbiology04/03/2021EMA starts rolling review of the Sputnik V COVID-19 vaccine
COVID-19 Vaccine (Vero Cell) InactivatedSinovac Life Sciences Co., Ltd04/05/2021EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated

For additional information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the rolling review, see:

Withdrawn from rolling review

Vaccine developers have withdrawn the following COVID-19 vaccines from the rolling review process:

VaccineVaccine developerKey milestonesMore information
CVnCoVCureVac AGRolling review started: 12/02/2021
Withdrawn from rolling review: 12/10/2021


How useful was this page?

Add your rating
30 ratings
14 ratings
10 ratings
21 ratings
122 ratings